Savara (NASDAQ:SVRA) Trading Down 4.7%

Savara Inc (NASDAQ:SVRAGet Free Report)’s share price was down 4.7% on Thursday . The stock traded as low as $3.99 and last traded at $4.04. Approximately 130,433 shares traded hands during trading, a decline of 85% from the average daily volume of 882,497 shares. The stock had previously closed at $4.24.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. JMP Securities reissued a “market outperform” rating and issued a $8.00 price objective on shares of Savara in a report on Monday, May 6th. Oppenheimer lifted their price objective on Savara from $9.50 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, May 21st. Piper Sandler boosted their price objective on Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Evercore ISI dropped their target price on Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, May 16th. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Savara in a research report on Monday, May 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $9.17.

Read Our Latest Stock Analysis on Savara

Savara Stock Performance

The company has a market cap of $547.23 million, a price-to-earnings ratio of -10.70 and a beta of 0.70. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. The stock’s fifty day simple moving average is $4.59 and its 200 day simple moving average is $4.62.

Savara (NASDAQ:SVRAGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, analysts anticipate that Savara Inc will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SVRA. ProShare Advisors LLC grew its position in shares of Savara by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after buying an additional 2,114 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Savara by 19.1% during the third quarter. State Board of Administration of Florida Retirement System now owns 25,780 shares of the company’s stock worth $97,000 after purchasing an additional 4,140 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Savara by 15.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares in the last quarter. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Savara in the 1st quarter valued at about $35,000. Finally, AJOVista LLC purchased a new position in Savara during the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.